title: Bacterial lipase and high-fat diets in canine exocrine pancreatic insufficiency: a new therapy of steatorrhea?
abstract: OBJECTIVE
  Nutrients and properties of lipases affect survival of lipolytic activity during aboral gastrointestinal transit. Whether different doses and formulations of bacterial lipase and diets affect steatorrhea was tested in pancreatic-insufficient dogs.
  
  
  METHODS
  A dose of 0-600,000 IU of powdered and 135,000 and 300,000 IU of liquid bacterial lipase was given with a standard meal to 5 dogs with ligated pancreatic ducts. In 4 dogs, 0 or 300,000 IU (normal 6-hour postprandial amount) of powder bacterial lipase was also given with five meals containing 850 kcal with different nutrient caloric densities (mixture design). Coefficients of fat absorption during 72-hour fecal balance studies were used to assess treatments.
  
  
  RESULTS
  With the standard meal, powder bacterial lipase reduced steatorrhea in a dose-dependent manner (P = 0.03), and 135,000 and 300,000 IU of the liquid form decreased steatorrhea more than powder bacterial lipase (P = 0.017 and 0.057, respectively). Coefficients of fat absorption with 300,000 IU of powder bacterial lipase correlated (r2 = 0.79; P < 0.001) with increasing proportions of fat calories in diets.
  
  
  CONCLUSIONS
  Liquid bacterial lipase decreases steatorrhea more than powder, and 300,000 IU of powder bacterial lipase ingested with high-fat meals corrects canine pancreatic steatorrhea. The combination of adequate mixing of small amounts (milligrams) of bacterial lipase and high-fat meals abolishes canine steatorrhea and may abolish human pancreatic steatorrhea.
authors.affiliation: Gastroenterology Research Unit, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: A
authors.initials: A
authors.lastname: Mizumoto
authors.forename: M G
authors.initials: MG
authors.lastname: Sarr
authors.forename: E P
authors.initials: EP
authors.lastname: DiMagno
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000494:pharmacology; D002446:Celiac Disease / Q000628:therapy*; D004041:Dietary Fats / Q000494:pharmacology*; D004195:Disease Models, Animal; D004285:Dogs; D010188:Exocrine Pancreatic Insufficiency / Q000628:therapy*; D005260:Female; D008049:Lipase / Q000494:pharmacology*
chemical_list: D001426:Bacterial Proteins; D004041:Dietary Fats; D008049:Lipase